iBio, Inc. (IBIO) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US4510337086
iBio, Inc. financials
| Fiscal year | 2025 | 2026 |
|---|---|---|
| Revenue | 400,000.00 USD | 100,000.00 USD |
| Operating income | -18.60 m USD | -35.14 m USD |
| EBIT | -18.60 m USD | -35.14 m USD |
| Net income | -18.38 m USD | -33.04 m USD |
| Diluted EPS – continuing operations | -1.75 USD | -0.32 USD |
Full history since 2007, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About iBio, Inc.
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies. In addition, the company is developing, an antibody therapeutics to treat glioblastoma and other cancers by selectively killing EGFRvIII tumor cells without destroying healthy tissue; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
More stocks
- Allied Biotech Corporation (1780.TWO)
- Incheon City G (034590.KS)
- NTF Intergroup (Thailand) Public Company Limited (NTF.BK)
- Mediaco Holding Inc. (MDIA)
- First Bankers Trustshares Inc (FBTT)
- Vittia Fertilizantes (VITT3.SA)
- Mars Semiconductor Corp. (6708.TWO)
- Faron Pharmaceuticals Oy (FARON.HE)
- Hwaseung Corporation Co Ltd (013520.KS)
- Tenaya Therapeutics, Inc. (TNYA)
- LapWall Oyj (LAPWALL.HE)
- Sempio Foods Co (248170.KS)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.